Skip to main content
. 2003 Jan;71(1):393–400. doi: 10.1128/IAI.71.1.393-400.2003

FIG. 5.

FIG. 5.

Upregulating CD36 increases phagocytosis of stage I and IIA gametocytes. (A) Human Mφs were incubated for 48 h with PPARγ-RXR agonists (5 μM 15d-PGJ2 and 1 μM 9-cis-RA) and processed for flow cytometry. In Mφs that were incubated with PPARγ-RXR agonists (black lines), there was an increase in CD36 surface levels compared to the levels in untreated Mφs (grey lines). (B) Phagocytosis assays were carried out by using adherent Mφs that had been incubated for 48 h with PPARγ-RXR agonists. Phagocytosis of nonopsonized erythrocytes containing stage I and IIA gametocytes was increased in Mφs treated with 5 μM 15d-PGJ2 and 1 μM 9-cis-RA (15d+9-cis) by 66.6% ± 9.4% (mean ± standard deviation) compared to phagocytosis in the controls (P < 0.01; n = 3) (one asterisk). Blocking CD36 with 10 μg of FA6 per ml in untreated Mφs resulted in a mean reduction in phagocytosis of 53.9% (P < 0.01; n = 3) (two asterisks), whereas anti-CD36 blockade of treated Mφs caused a mean reduction in phagocytosis of 52.0% (P < 0.01; n = 3) (three asterisks). PI, phagocytic index.